Meeting Register Page

The Future of HIV Biomedical Prevention Research
Recent news about HIV biomedical prevention research has been a mixed bag: very encouraging results from long-acting pre-exposure prophylaxis (PrEP) trials, but a disappointing lack of significant protection achieved with experimental HIV vaccines. Furthermore, the entire research effort has had to wrestle with the impact of the COVID-19 pandemic.

Join Abraham Johnson, TAG's Community Engagement Officer, for a look at the future of HIV biomedical prevention research presented by Carl Dieffenbach, Director of the Division of AIDS at the National Institute for Allergy and Infectious Diseases (NIAID).

Sep 14, 2021 02:00 PM in Eastern Time (US and Canada)

Registration is closed.